Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 08 04 2020
accepted: 18 06 2021
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Spi-1 Proto-Oncogene (SPI1) fusion genes are recurrently found in T-cell acute lymphoblastic leukemia (T-ALL) cases but are insufficient to drive leukemogenesis. Here we show that SPI1 fusions in combination with activating NRAS mutations drive an immature T-ALL in vivo using a conditional bone marrow transplant mouse model. Addition of the oncogenic fusion to the NRAS mutation also results in a higher leukemic stem cell frequency. Mechanistically, genetic deletion of the β-catenin binding domain within Transcription factor 7 (TCF7)-SPI1 or use of a TCF/β-catenin interaction antagonist abolishes the oncogenic activity of the fusion. Targeting the TCF7-SPI1 fusion in vivo with a doxycycline-inducible knockdown results in increased differentiation. Moreover, both pharmacological and genetic inhibition lead to down-regulation of SPI1 targets. Together, our results reveal an example where TCF7-SPI1 leukemia is vulnerable to pharmacological targeting of the TCF/β-catenin interaction.

Identifiants

pubmed: 34230493
doi: 10.1038/s41467-021-24442-9
pii: 10.1038/s41467-021-24442-9
pmc: PMC8260768
doi:

Substances chimiques

MAS1 protein, human 0
Membrane Proteins 0
Oncogene Proteins, Fusion 0
Proto-Oncogene Mas 0
Proto-Oncogene Proteins 0
T Cell Transcription Factor 1 0
TCF7 protein, human 0
Trans-Activators 0
beta Catenin 0
proto-oncogene protein Spi-1 0
GTP Phosphohydrolases EC 3.6.1.-
NRAS protein, human EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4164

Références

J Hematol Oncol. 2012 May 08;5:22
pubmed: 22569057
Development. 1999 Jun;126(14):3131-48
pubmed: 10375504
Gigascience. 2018 Jul 1;7(7):
pubmed: 30010766
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell Rep. 2013 Dec 26;5(6):1704-13
pubmed: 24332856
Science. 2020 Feb 21;367(6480):
pubmed: 32079746
Nature. 2011 Aug 03;476(7358):63-8
pubmed: 21814277
PLoS Med. 2016 Dec 20;13(12):e1002200
pubmed: 27997540
Nucleic Acids Res. 2012 Aug;40(15):e114
pubmed: 22718975
J Biol Chem. 1992 Apr 25;267(12):8530-6
pubmed: 1569101
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Leukemia. 2015 May;29(5):1032-40
pubmed: 25371176
Science. 1997 Mar 21;275(5307):1790-2
pubmed: 9065403
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Blood. 2014 Nov 13;124(20):3092-100
pubmed: 25193870
Cancer Cell. 2017 Nov 13;32(5):552-560
pubmed: 29136503
Nat Genet. 2006 Jan;38(1):27-37
pubmed: 16311598
Genome Res. 2021 Mar;31(3):448-460
pubmed: 33441414
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Nat Genet. 2004 Jun;36(6):624-30
pubmed: 15146183
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
Leukemia. 2018 Jun;32(6):1358-1369
pubmed: 29740158
Nat Commun. 2019 Jul 16;10(1):3120
pubmed: 31311926
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Nat Genet. 2017 Aug;49(8):1274-1281
pubmed: 28671687
Genome Res. 2017 May;27(5):737-746
pubmed: 28100585
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Nature. 2008 May 22;453(7194):529-33
pubmed: 18463637
Genome Biol. 2019 Mar 22;20(1):63
pubmed: 30902100
Cancer Discov. 2018 May;8(5):616-631
pubmed: 29496663
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1486-91
pubmed: 16432184
Elife. 2018 Nov 09;7:
pubmed: 30412053
Mol Cell Biol. 1993 May;13(5):2929-41
pubmed: 8474451
Blood. 2011 Jul 14;118(2):368-79
pubmed: 21586752
Eur J Immunol. 2015 Mar;45(3):932-42
pubmed: 25408420
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Nature. 1988 Jan 21;331(6153):277-80
pubmed: 2827041
Genome Res. 2017 May;27(5):722-736
pubmed: 28298431
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nat Genet. 2013 Feb;45(2):186-90
pubmed: 23263491
Genome Res. 2013 Dec;23(12):2115-25
pubmed: 24056532
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Cancer Cell. 2019 Dec 9;36(6):630-644.e9
pubmed: 31735627
Cancer Cell. 2018 Aug 13;34(2):271-285.e7
pubmed: 30107177
EMBO Mol Med. 2021 Mar 5;13(3):e12670
pubmed: 33555144
Chem Biol. 2010 Jun 25;17(6):646-57
pubmed: 20609414
Nat Genet. 2006 Nov;38(11):1269-77
pubmed: 17041602
Nat Rev Immunol. 2014 Aug;14(8):529-45
pubmed: 25060579
Genome Biol. 2016 Feb 17;17:29
pubmed: 26887813
Nature. 1995 Mar 2;374(6517):70-4
pubmed: 7870176
Nat Cancer. 2021 Mar;2(3):284-299
pubmed: 34151288
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cancer Discov. 2019 Jun;9(6):796-811
pubmed: 31018969
Leukemia. 2018 Apr;32(4):941-951
pubmed: 29151585
Leukemia. 2004 Apr;18(4):685-92
pubmed: 14990973
Cell. 2012 Mar 2;148(5):886-95
pubmed: 22385958
Development. 2013 Mar;140(6):1207-19
pubmed: 23444353
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Blood. 2019 Oct 17;134(16):1323-1336
pubmed: 31492675
Immunity. 2002 Feb;16(2):285-96
pubmed: 11869688
Blood. 2002 Aug 1;100(3):998-1007
pubmed: 12130514
Immunity. 2018 Feb 20;48(2):243-257.e10
pubmed: 29466756
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4349-63
pubmed: 19382896
Science. 2014 Dec 12;346(6215):1373-7
pubmed: 25394790
Blood. 1991 Mar 15;77(6):1218-27
pubmed: 1705833
PLoS Genet. 2013;9(12):e1003997
pubmed: 24367274
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106

Auteurs

Quentin Van Thillo (Q)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.
Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.

Jolien De Bie (J)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.
Center for Human Genetics, UZ Leuven, Leuven, Belgium.

Janith A Seneviratne (JA)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Sofie Demeyer (S)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.
Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.

Sofia Omari (S)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Anushree Balachandran (A)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Vicki Zhai (V)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Wai L Tam (WL)

Technology Innovation Lab, VIB, Gent, Belgium.

Bram Sweron (B)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.

Ellen Geerdens (E)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.
Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.

Olga Gielen (O)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.

Sarah Provost (S)

Department of Human Genetics, KU Leuven, Leuven, Belgium.
Center for Cancer Biology, VIB, Leuven, Belgium.

Heidi Segers (H)

Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.
Department of Pediatric Hemato-Oncology, UZ Leuven, Leuven, Belgium.

Nancy Boeckx (N)

Department of Oncology, KU Leuven, Leuven, Belgium.
Department of Laboratory Medicine, UZ Leuven, Leuven, Belgium.

Glenn M Marshall (GM)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.

Belamy B Cheung (BB)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Kiyotaka Isobe (K)

Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Itaru Kato (I)

Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Junko Takita (J)

Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Timothy G Amos (TG)

Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.

Ira W Deveson (IW)

Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.
St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.

Hannah McCalmont (H)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Richard B Lock (RB)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.

Ethan P Oxley (EP)

Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.

Maximilian M Garwood (MM)

Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.

Ross A Dickins (RA)

Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.

Anne Uyttebroeck (A)

Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.
Department of Oncology, KU Leuven, Leuven, Belgium.
Department of Pediatric Hemato-Oncology, UZ Leuven, Leuven, Belgium.

Daniel R Carter (DR)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
School of Biomedical Engineering, University of Technology, Sydney, NSW, Australia.

Jan Cools (J)

Department of Human Genetics, KU Leuven, Leuven, Belgium. jan.cools@kuleuven.be.
Center for Cancer Biology, VIB, Leuven, Belgium. jan.cools@kuleuven.be.
Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium. jan.cools@kuleuven.be.

Charles E de Bock (CE)

Children's Cancer Institute, UNSW Sydney, Lowy Cancer Research Centre, Sydney, NSW, Australia. cdebock@ccia.org.au.
School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia. cdebock@ccia.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH